Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Hydroxychloroquine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 10 Breast Neoplasms 7 Prostatic Neoplasms 6 Colorectal Neoplasms 6 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Multiple Myeloma 3 Melanoma 3 Gastrointestinal Neoplasms 3 COVID-19 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumor 2 Recurrence 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Leukemia 2 Glioblastoma 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Adenocarcinoma of Lung 2 Urologic Diseases 1 Untreated Resectable Pancreatic Adenocarcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Respiratory Distress Syndrome 1 Resectable Localized Prostate Cancer 1

Interventions

Cyclophosphamide 20 blinatumomab 16 fludarabine 13 Cytarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 9 Rituximab 7 Dexamethasone 7 Methotrexate 6 Lenalidomide 6 Daunorubicin 6 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Mercaptopurine 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Cladribine 3 Busulfan 3 Asparaginase 3 tislelizumab 2 tisagenlecleucel 2 thymoglobulin 2 pembrolizumab 2 palbociclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2025-03-11

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡